Journal of Clinical Toxicology
Open Access

Collin A Hovinga

Biography

Dr. Hovinga completed his Bachelor of Science Degree in Biology (1991) and Doctor of Pharmacy (1997) degrees from Creighton University in Omaha, Nebraska.  After which he pursued a Residency and Fellowship in Pediatric Pharmacotherapy (1997-2000) with emphasis in Pediatric Neuroscience at the University of Tennessee, Memphis, LeBonheur Children’s Medical Center.  He has had a Fellowship at the Food and Drug Administration Office of Clinical Pharmacology (2009) and a Masters of Epidemiology from the University of Tennessee Health Science Center (2010).  He is currently Director of Research at Dell Children’s Medical Center and Associate Professor of Clinical Pharmacy at UT Austin School of Pharmacy. Doctor Hovinga has been active in studying the genetic effects on the susceptibility of neonates to hypoxia-induced seizures and in studying the pharmacogenetics of medications in the treatment of epilepsy and autism.  Dr. Hovinga is recognized as an expert in neuropharmacology.  Dr. Hovinga has had leadership roles in neuroprotective drug pharmacology NIH projects (Clinical Investigations for Neuroprotective Agents in Parkinson’s Syndrome (CINAPS)) and for Huntington’s Disease (SET-HD).  Dr. Hovinga’s understanding of developmental pharmacology and pediatric brain injury has made him unique in the pharmacology arena and has led to him being a journal reviewer and an invited speaker at many national organizational meetings.

Research Interest

Pediatric Pharmacotherapy, Pediatric Neuroscience.